Discover future ready bioactive proteins: whitepaper

From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies, says Abcam. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced to the highest standards to ensure the same reproducible results over a five-15 years development timeline.

The company’s whitepaper aims to demonstrates how its premium grade bioactive proteins set new standards for consistency, bioactivity, and reproducibility to help you meet the challenges ahead with confidence. It says that the consistent performance these premium grade bioactive proteins provide enables you a smooth transition from research to clinical development, saving your time and resources

This whitepaper demonstrates:

  • Abcam’s manufacturing workflow for producing premium grade recombinant human cytokines and growth factors
  • How it accesses the purity and batch-to-batch consistency of its premium range bioactive proteins
  • Biophysical QC and bioactive assay batch data for the production of three premium grade bioactive proteins: two recombinant human cytokines, TNF-α and IL-3, and one recombinant human growth factor EGF

Download the whitepaper here

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free